CymaBay Therapeutics
7999 Gateway Blvd
Suite 130
Newark, CA 94560
Company Information
CymaBay Therapeutics (NASDAQ: CBAY)
We are a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need. In addition to evaluating seladelpar in primary biliary cholangitis (PBC) and NonAlcoholic SteatoHepatitis (NASH), our phase 3 ready program for arhalofenate in gout has been licensed in the U.S. to Kowa Pharmaceuticals America, Inc. We also have two product programs in earlier development that feature unique mechanisms of action and have potential in liver and chronic diseases.
Stock Information
| Last | Change | Volume |
Company Information
Investor Relations
Sujal Shah
(510) 293-8800
investors@cymabay.com
Recent News
Upcoming Event
Jun
5
2018
9:00 am PT
Annual Meeting of Stockholders
June 5, 2018 at 9:00 am PT
Pacific Research Center, 7677 Gateway Blvd., Conference Center 2nd Floor, Apex Room, Newark, CA 94560